Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)

Multiple Sclerosis Clinical Trial

Official title:

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00674934
• Other study ID #: GAAD-MS-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: May 6, 2008
• Last updated: January 2, 2009
• Start date: May 2008
• Est. completion date: June 2010

Study information

• Verified date: January 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health CanadaUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Multiple sclerosis (abbreviated MS) is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. This study will investigate the use of far infrared radiation for MS control, management and treatment.

Description:

MS a demyelinating disease, is any disease of the nervous system in which the myelin sheath of neurons is damaged. This impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved.

MS affects the areas of the brain and spinal cord known as the white matter. White matter cells carry signals between the grey matter areas, where the processing is done, and the rest of the body. More specifically, MS destroys oligodendrocytes which are the cells responsible for creating and maintaining a fatty layer, known as the myelin sheath, which helps the neurons carry electrical signals.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have MS.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5
• Est. completion date: June 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with MS

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Radiation:
• Far Infrared Radiation (5µm to 20µm wavelength)
Far Infrared Radiation (5µm to 20µm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment of MS		2 years	No
Secondary	Rehabilitation of MS Patients		2 Years	No